KNOWLEDGE SHARING AND CAPACITY BUILDING

- The return of in-person format entailed Q&A with discussion, face-to-face networking, and building relationships with vendors.
- Premiere of roundtable discussions created the opportunity to focus on specific topics in-depth and sparked lively discussions.
- Introduction of gene editing and supply chain sessions.
- Additional discussion time in the AAV and Potency session prompted active participation from the audience in these discussions.

Cell & Gene Therapy Products 2022 BY THE NUMBERS

- **Attendee Participants**
  - In-Person - 163
  - Virtual - 201
  - First Time - 185

- **Regulators Participation**
  - 21

- **Company Participation**
  - 102

**Country Participation**

21

- Austria | Belgium | Brazil | Canada | Czech Republic | Denmark |
- Finland | France | Germany | India | Israel | Italy | Japan |
- Netherlands | Portugal | Singapore | Spain | Sweden |
- Switzerland | United Kingdom | United States